(via NewsDirect)
By
![On the Heels of a Successful Phase 2a Trial, Acurx is Looking to Post Topline Results from a Muti-Center Phase 2b Trial by Mid-Year – The Results Could be Game-Changing](https://public.newsdirect.com/643585411/qg0vDlWv.jpg)
C. diffis a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon.Approximately 600,000 are diagnosed with C. diffeach year in
The current treatment for C. diffis vancomycin, an antibiotic that is typically prescribed for serious pathogenic infections. While the drug is safe and has proven successful, the antibiotic has been on the market for 65 years and its effectiveness has been steadily declining as more and more bacteria have become resistant to it, consistent with the path of virtually all other antibiotics over time.
Understanding the need for a new antibiotic to treat C. diff,
During the Phase 2a clinical trial, 100% of the first 10 patients were clinically cured of C. diffand did not have a recurrent infection within a 28-day period after the end of treatment with no safety concerns. Because of these strong results, the
The current standard of care, vancomycin, has an average clinical cure rate of 80% with a 30% chance of recurrent infection. In comparison, ibezapolstat would be a far more suitable drug with a higher success rate if current data holds in late-stage development. Acurx is expecting similarly strong results for their Phase 2b clinical trial. The company is expected to release topline results by mid-2023 if the FDA agrees with the company’s plan for an interim analysis.
If the trials continue to be a success and ibezapolstat demonstrates statistical noninferiority compared to vancomycin in curing primary C. diff, it could win FDA approval and be used as first line therapy. But of equal, or even greater, importance are the results being shown in preventing recurrence -- the major cause of C. diff morbidity and mortality, and the principal contributor to C. diff’s
Being able to reduce or eliminate recurrence would be a game-changing development in treating an infection that affects so many individuals, especially amid rising bacterial resistance to vancomycin.
Ibezapolstat’s potential game-changing status would be further assured if it scores well in two exploratory endpoints in the current Phase 2b trial – the number of disease-free patients at days 60 and 90 (two time points not included on any product labeled for C. diff.) and if it continues to demonstrate restoration of the healthy microbiome of C. diff patients during the treatment process.
Click here for more information about Acurx.
About
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Photo by
Contact Details
+1 917-533-1469
davidluci@acurxpharma.com
Company Website
https://www.acurxpharma.com/
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source